About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT05668000

Mobile App for Heart Failure

The investigators developed a mobile health platform to self-management in HF. The aim of this study is to evaluate whether this smartphone app-based intervention can improve symptoms of HF when compa...

Lead sponsor: Seoul National University Bundang Hospital•7 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Seoul National University Bundang Hospital

Collaborators

KT Corporation

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients aged 20 years or older hospitalized for acute heart failure.
•Patients who have obvious symptoms or sign of HF at admission
•N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥400 pg/mL or brain natriuretic peptide (BNP) ≥100 pg/mL.
•participants should be able to use smartphone well.

Exclusion Criteria

•Patients who have baseline systolic blood pressure \<90 mmHg or resting heart rate \<50 beats per minutes
•Patients who cannot use smartphone
•Patients who had cardiac implantable electronic device will be excluded

Related studies

MRI Assessment of Pulmonary Edema in Acute Heart Failure

NCT03999138 · Acute Heart Failure, Pulmonary Edema With Heart Failure

RECRUITINGPhase 2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964 · Fontan Circulation, Single Ventricle Heart Disease, and more

Biomarker Guided Discharge of Heart Failure Patients

NCT03103932 · Heart Failure; With Decompensation

Assessing Systemic Circulation and LV Performance in Adults

NCT04347655 · Heart Failure

RECRUITINGPhase 2

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011 · Heart Failure With Preserved Ejection Fraction

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 1, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment84

Start dateOct 2022

Last updatedNov 1, 2023

Condition

Locations shown

Keimyung University Hospital

Daegu

Seoul National University Bundang Hospital

Seongnam

Catholic University college of medicine

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 1, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions